Cargando…

Incidence and Geographical Variation of Amyotrophic Lateral Sclerosis (ALS) in Southern Germany – Completeness of the ALS Registry Swabia

Objective of this paper was to investigate the incidence, potential geographical clusters and the completeness of the amyotrophic lateral sclerosis (ALS) registry in Southern Germany (Swabia). Age-standardized incidence rates (ASR) and ratios (SIR) as well as 95% confidence intervals (CI) were estim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uenal, Hatice, Rosenbohm, Angela, Kufeldt, Johannes, Weydt, Patrick, Goder, Katharina, Ludolph, Albert, Rothenbacher, Dietrich, Nagel, Gabriele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983245/ https://www.ncbi.nlm.nih.gov/pubmed/24722455 http://dx.doi.org/10.1371/journal.pone.0093932

Ejemplares similares

Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) - registry Swabia
por: Nagel, Gabriele, et al.
Publicado: (2013)

Association of Insulin-like Growth Factor 1 Concentrations with Risk for and Prognosis of Amyotrophic Lateral Sclerosis – Results from the ALS Registry Swabia
por: Nagel, Gabriele, et al.
Publicado: (2020)

Association of blood lipids with onset and prognosis of amyotrophic lateral sclerosis: results from the ALS Swabia registry
por: Michels, Sebastian, et al.
Publicado: (2023)

Cystatin C based estimation of chronic kidney disease and amyotrophic lateral sclerosis in the ALS registry Swabia: associated risk and prognostic value
por: Nagel, Gabriele, et al.
Publicado: (2023)

Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis – results from a population- based ALS registry in Germany
por: Nagel, Gabriele, et al.
Publicado: (2017)

Saccadic intrusions in amyotrophic lateral sclerosis (ALS)
por: Becker, Wolfgang, et al.
Publicado: (2019)

Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany
por: Schönfelder, Erik, et al.
Publicado: (2020)

Cardiac Findings in Amyotrophic Lateral Sclerosis: A Magnetic Resonance Imaging Study
por: Rosenbohm, Angela, et al.
Publicado: (2017)

Metabolic alterations precede neurofilament changes in presymptomatic ALS gene carriers
por: Dorst, Johannes, et al.
Publicado: (2023)

Preliminary Results of National Amyotrophic Lateral Sclerosis (ALS) Registry Risk Factor Survey Data
por: Bryan, Leah, et al.
Publicado: (2016)

Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol
por: Albanese, Alberto, et al.
Publicado: (2022)

Comparison of Sirtuin 3 Levels in ALS and Huntington’s Disease—Differential Effects in Human Tissue Samples vs. Transgenic Mouse Models
por: Buck, Eva, et al.
Publicado: (2017)

Perception of Emotional Facial Expressions in Amyotrophic Lateral Sclerosis (ALS) at Behavioural and Brain Metabolic Level
por: Aho-Özhan, Helena E. A., et al.
Publicado: (2016)

CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions
por: Mehta, Paul, et al.
Publicado: (2017)

Motoneuron firing in amyotrophic lateral sclerosis (ALS)
por: de Carvalho, Mamede, et al.
Publicado: (2014)

Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors
por: Sebastião, Ana M., et al.
Publicado: (2018)

Characteristics of Sensory Neuron Dysfunction in Amyotrophic Lateral Sclerosis (ALS): Potential for ALS Therapy
por: Seki, Soju, et al.
Publicado: (2023)

Alterations in Leptin Signaling in Amyotrophic Lateral Sclerosis (ALS)
por: Ferrer-Donato, Agueda, et al.
Publicado: (2021)

Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015
por: RAYMOND, JAIME, et al.
Publicado: (2019)

A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial
por: Lombardo, Flavia L., et al.
Publicado: (2023)

Environmental Risk Factors and Amyotrophic Lateral Sclerosis (ALS): A Case-Control Study of ALS in Michigan
por: Yu, Yu, et al.
Publicado: (2014)

Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS)
por: Mavlyutov, Timur A., et al.
Publicado: (2015)

Amyotrophic Lateral Sclerosis (ALS) Awareness Month — May 2013
Publicado: (2013)

Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design
por: Fournier, Christina N.
Publicado: (2022)

Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany
por: Hahn, Andreas, et al.
Publicado: (2022)

Correction to: Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany
por: Hahn, Andreas, et al.
Publicado: (2022)

Recruitment of population-based controls for ALS cases from the National ALS Registry
por: BEAR, TODD M., et al.
Publicado: (2021)

Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry’s Research Notification Mechanism
por: Mehta, Paul, et al.
Publicado: (2021)

Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral Sclerosis
por: Kittipeerapat, Natsinee, et al.
Publicado: (2023)

ALS2 mutations: Juvenile amyotrophic lateral sclerosis and generalized dystonia
por: Sheerin, Una-Marie, et al.
Publicado: (2014)

State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance
por: Wagner, Laurie, et al.
Publicado: (2016)

Genetics and Sex in the Pathogenesis of Amyotrophic Lateral Sclerosis (ALS): Is There a Link?
por: Trojsi, Francesca, et al.
Publicado: (2020)

Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
por: Park, Jin-Mo, et al.
Publicado: (2019)

MRI Study of Paraspinal Muscles in Patients with Amyotrophic Lateral Sclerosis (ALS)
por: Diamanti, Luca, et al.
Publicado: (2020)

The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS)
por: Ferrer‐Donato, Agueda, et al.
Publicado: (2021)

Delivery of nutritional management services to people with amyotrophic lateral sclerosis (ALS)
por: Halliday, Vanessa, et al.
Publicado: (2021)

A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany
por: Peseschkian, Tara, et al.
Publicado: (2021)

The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice
por: Akamatsu, Megumi, et al.
Publicado: (2016)

A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013
por: Horton, D. Kevin, et al.
Publicado: (2017)

Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives
por: Schischlevskij, Pavel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fe4gbj03ld0j9n44c5mkuvel7j